MCID: ART008
MIFTS: 40

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 36 54 44 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
KEGG 36 H01626
MeSH 44 D001162
SNOMED-CT 67 60625000
UMLS 70 C0003851

Summaries for Arteriosclerosis Obliterans

KEGG : 36 Arteriosclerosis obliterans (ASO) is one of the most common peripheral vascular diseases that causes ischemic symptoms of the lower limbs. Symptoms include discomfort, numbness, intermittent claudication, or even gangrene and ulceration. The risk factors of ASO include age, male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, chronic renal failure, and hyperhomocysteinemia. There are no definitive treatments for ASO. The efficacy of surgical treatment is not satisfactory, and medication is required to maintain the postoperative vascular patency. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Adsorption of low-density lipoprotein (LDL) has also been applied for the treatment of ASO. At present, the diagnosis of ASO depends on several clinical tests, such as angiography, estimations of ankle/brachial index (ABI), and pulse-wave velocity (PWV), as well as the measurement of circulating hs-CRP levels. However, these examinations can only be detectable when ASO already developed, and there was no predictable markers for ASO in its earlier stages. Recent studies have reported that some micro RNAs could be serum markers for early-stage ASO.

MalaCards based summary : Arteriosclerosis Obliterans is related to buerger disease and peripheral vascular disease. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are MicroRNAs in cancer and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Aspirin and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and endothelial.

Wikipedia : 73 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 buerger disease 31.1 VCAM1 ICAM1
2 peripheral vascular disease 31.0 VCAM1 SELP IL6
3 aortic aneurysm, familial abdominal, 1 30.6 VCAM1 IL6 ICAM1
4 arteriosclerosis 30.6 VCAM1 SELP MIR21 MIR133A1 IL6 ICAM1
5 intermediate coronary syndrome 30.5 VCAM1 SELP IL6
6 coronary stenosis 30.3 MIR21 IL6 ICAM1
7 limb ischemia 30.3 MIR210 MIR21 IL6 ICAM1 HGF
8 angina pectoris 30.3 IL6 ICAM1 ADIPOQ
9 chronic venous insufficiency 30.2 VCAM1 SELP ICAM1
10 venous insufficiency 30.2 VCAM1 SELP ICAM1
11 ischemia 30.1 SELP MIR21 ICAM1 HGF
12 atherosclerosis susceptibility 30.1 VCAM1 SELP IL6 ICAM1 ADIPOQ
13 vascular disease 30.1 VCAM1 SELP MIR21 IL6 ICAM1 ADIPOQ
14 carotid stenosis 30.1 VCAM1 SELP ICAM1 ADIPOQ
15 cerebrovascular disease 30.1 VCAM1 SELP MIR21 IL6 ICAM1 ADIPOQ
16 peripheral artery disease 30.0 VCAM1 SELP IL6 ICAM1 HGF
17 type 1 diabetes mellitus 29.6 MIR210 MIR21 IL6 ICAM1 ADIPOQ
18 systemic lupus erythematosus 29.4 VCAM1 SELP MIR210 MIR21 IL6 ICAM1
19 heart disease 29.1 VCAM1 SELP MIR210 MIR21 IL6 ICAM1
20 lipoprotein quantitative trait locus 28.9 VCAM1 SELP MIR22 MIR21 MIR133A1 IL6
21 arteries, anomalies of 28.7 VCAM1 MIR22 MIR210 MIR21 MIR133A1 IL6
22 intermittent claudication 10.7
23 aortic aneurysm 10.4
24 hypercholesterolemia, familial, 1 10.4
25 obesity-hypoventilation syndrome 10.4 IL6 ADIPOQ
26 aneurysm 10.3
27 actinic prurigo 10.3 VCAM1 ICAM1
28 rheumatoid vasculitis 10.3 VCAM1 ICAM1
29 shwartzman phenomenon 10.3 VCAM1 ICAM1
30 mooren's ulcer 10.3 VCAM1 ICAM1
31 limbal stem cell deficiency 10.3 VCAM1 ICAM1
32 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.2
33 lipid metabolism disorder 10.2
34 end stage renal disease 10.2
35 48,xyyy 10.2
36 macular degeneration, age-related, 9 10.2 VCAM1 SELP ICAM1
37 retinal vascular occlusion 10.2 SELP IL6 ICAM1
38 immune-complex glomerulonephritis 10.2 VCAM1 SELP ICAM1
39 apnea, obstructive sleep 10.2 IL6 ICAM1 ADIPOQ
40 vein disease 10.2 SELP IL6 ICAM1
41 common cold 10.2 SELP IL6 ICAM1
42 post-thrombotic syndrome 10.2 VCAM1 IL6 ICAM1
43 plasmodium vivax malaria 10.2 VCAM1 IL6 ICAM1
44 erythema nodosum 10.2 VCAM1 IL6 ICAM1
45 takayasu arteritis 10.2 VCAM1 IL6 ICAM1
46 hypertriglyceridemia, familial 10.2
47 coronary heart disease 1 10.2
48 intracranial berry aneurysm 10.2 VCAM1 IL6 ICAM1
49 peritonitis 10.2 SELP IL6 ICAM1
50 fabry disease 10.2 VCAM1 IL6 ICAM1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Remifentanil Approved Phase 4 132875-61-7 60815
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Probucol Approved, Investigational Phase 4 23288-49-5 4912
7 Vasodilator Agents Phase 4
8 Anesthetics Phase 4
9 Hypnotics and Sedatives Phase 4
10 Narcotics Phase 4
11 Anesthetics, General Phase 4
12 Anesthetics, Inhalation Phase 4
13 Anesthetics, Intravenous Phase 4
14 Platelet Aggregation Inhibitors Phase 4
15 Analgesics, Opioid Phase 4
16 Analgesics Phase 4
17 Anti-Asthmatic Agents Phase 4
18 Fibrinolytic Agents Phase 4
19 Respiratory System Agents Phase 4
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Phosphodiesterase Inhibitors Phase 4
22 Neuroprotective Agents Phase 4
23 Protective Agents Phase 4
24 Bronchodilator Agents Phase 4
25 Anticholesteremic Agents Phase 4
26 Antimetabolites Phase 4
27 Antioxidants Phase 4
28 Lipid Regulating Agents Phase 4
29 Hypolipidemic Agents Phase 4
30
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
31 Anticoagulants Phase 2
32
Heparin Approved, Investigational 9005-49-6 772 9812414
33 Calcium, Dietary
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors
35 Anti-Bacterial Agents
36 Antibiotics, Antitubercular
37 calcium heparin
38
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
3 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
4 Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities-A Phase II Multi-center Randomised Controlled Trial Unknown status NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
5 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Unknown status NCT02864654 Phase 1, Phase 2
6 Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells Completed NCT00753025 Phase 2
7 A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD) Recruiting NCT02501018 Phase 2 SOC
8 Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran of Phase II Clinical Trial Recruiting NCT04197323 Phase 2 Alprostadil liposomes for injection
9 Study of the Mechanisms of the Arterial Calcification of the Members Subordinates in the Diabetes (Implication of the System RANK / RANKL / OSTEOPROTEGERINE) Unknown status NCT02431234
10 Therapeutic Angiogenesis Using Cell Transplantation (TACT) Study at Nagoya Unknown status NCT00145262
11 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
12 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F): a RCTrial to Evaluate the Effect of LDL-apheresis on the Recovery of Diabetic Ulcers in Patients With Peripheral Vasculopathy Not Susceptible to Revascularization. Completed NCT01518205
13 A Prospective, Multicenter, Observational Study of Short and Long-term Outcome in Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon (PROMISING Study) Recruiting NCT04826705

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

40
Bone Marrow, Bone, Endothelial, Heart, Smooth Muscle, Skeletal Muscle, Kidney

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 1031)
# Title Authors PMID Year
1
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. 61 54
19225945 2009
2
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. 61 54
17126824 2007
3
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. 54 61
15238569 2004
4
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. 54 61
12882890 2003
5
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. 61 54
11505083 2001
6
[A new medical treatment for thrombosis by genetic engineering]. 61 54
10429451 1999
7
Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. 61 54
10373220 1999
8
[Blood coagulation disorders observed in arteriosclerosis obliterans]. 61 54
8808808 1996
9
Suppression of miR-4463 promotes phenotypic switching in VSMCs treated with Ox-LDL. 61
33245416 2021
10
MicroRNA-130a inhibits proliferation of vascular smooth muscle cells by suppressing autophagy via ATG2B. 61
33611856 2021
11
Differences in lesion characteristics and patient background associated with the medium-term clinical outcomes of bare-metal and first-, second- and third-generation drug-eluting stents. 61
32918197 2021
12
Analysis of Risk Factors for Bronchopleural Fistula after Surgical Treatment of Lung Cancer. 61
32224595 2020
13
Loss of GRB2 associated binding protein 1 in arteriosclerosis obliterans promotes host autophagy. 61
33323827 2020
14
Ameliorative effects of the traditional Chinese medicine formula Qing-Mai-Yin on arteriosclerosis obliterans in a rabbit model. 61
33073642 2020
15
Antisense long non‑coding RNA WEE2‑AS1 regulates human vascular endothelial cell viability via cell cycle G2/M transition in arteriosclerosis obliterans. 61
33174040 2020
16
Effects of M-1, a Major Metabolite of Sarpogrelate, on 5-HT-Induced Constriction of Isolated Human Internal Thoracic Artery. 61
32999137 2020
17
Author's response to the comments on "Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes". 61
33008686 2020
18
Comments on preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. 61
33008687 2020
19
Administration of Slow-Release Synthetic Prostacyclin Agonist Promoted Angiogenesis and Skeletal Muscle Regeneration for Limb Ischemia. 61
32637444 2020
20
Neutrophil gelatinase-associated lipocalin as an early predictor of contrast-induced nephropathy following endovascular therapy for arteriosclerosis obliterans. 61
32925711 2020
21
A risk predictor of restenosis after superficial femoral artery stent implantation: relevance of mean platelet volume. 61
32770951 2020
22
[Clinical study on treatment of chronic infection of foot and ankle with lower extremity ischemic diseases by tibial transverse transport combined with antibiotic embedded bone cement]. 61
32794665 2020
23
TIM‑3 inhibits PDGF‑BB‑induced atherogenic responses in human artery vascular smooth muscle cells. 61
32467985 2020
24
The relationship between neutrophil-lymphocyte ratio and in-stent restenosis in superficial femoral artery. 61
32583853 2020
25
Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. 61
32306290 2020
26
Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial. 61
32541643 2020
27
Predictors of fatal outcome after severe necrotizing fasciitis: Retrospective analysis in a tertiary hospital for 20 years. 61
32414564 2020
28
Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. 61
31227298 2020
29
Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans. 61
31449956 2020
30
Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Predict Severity and Prognosis of Lower Limb Arteriosclerosis Obliterans. 61
31655109 2020
31
Establishment of optimal exercise therapy using near-infrared spectroscopy monitoring of tissue muscle oxygenation after therapeutic angiogenesis for patients with critical limb ischemia: A multicenter, randomized, controlled trial. 61
32072074 2020
32
Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-derived Mononuclear Cell Implantation in Patients with No-option Critical Limb Ischemia. 61
32273917 2020
33
A case of ischemic osteopathy in a hemodialysis patient with advanced peripheral artery disease. 61
31637589 2020
34
Incidence, Characteristics, Laboratory Findings and Outcomes in Acro-Ischemia in COVID-19 Patients. 61
33262599 2020
35
Endothelin-1 and C Reactive Protein as Potential Biomarkers for Restenosis in Patients with Arteriosclerosis Obliterans. 61
32000546 2020
36
Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans. 61
31996054 2020
37
Expression and clinical significance of HSP27 and its phosphorylation in lower extremity arteriosclerosis obliterans. 61
32566403 2020
38
miR-21 regulates vascular smooth muscle cell function in arteriosclerosis obliterans of lower extremities through AKT and ERK1/2 pathways. 61
31749878 2019
39
Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway. 61
31410117 2019
40
MiR-126 promotes endothelial cell apoptosis by targeting PI3K/Akt in rats with lower limb arteriosclerosis obliterans. 61
31389593 2019
41
MiR-210 inhibits apoptosis of vascular endothelial cells via JAK-STAT in arteriosclerosis obliterans. 61
31389592 2019
42
Evaluation of Risk Factors for Limb-Specific Peripheral Vascular Events in Patients With Peripheral Artery Disease: A Post Hoc Analysis of the SEASON Prospective Observational Study. 61
30477334 2019
43
The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. 61
30487347 2019
44
Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. 61
31086577 2019
45
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. 61
31086587 2019
46
Effect of lncRNA H19 on the apoptosis of vascular endothelial cells in arteriosclerosis obliterans via the NF-κB pathway. 61
31173326 2019
47
[Femoral-popliteal Arteriosclerosis Obliterans:Review of Evidence-based Studies on Drug-eluting Endovascular Treatment]. 61
31060683 2019
48
Analysis of finger vein variety in patients with various diseases using vein authentication technology. 61
30565416 2019
49
Hospital Discharge Teaching for Patients with Peripheral Vascular Disease. 61
30736938 2019
50
A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis. 61
30446942 2019

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 VCAM1 SELP MIR22 MIR210 MIR21 MIR133A1

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.86 VCAM1 IL6 ICAM1 HGF
2 response to ethanol GO:0045471 9.74 VCAM1 ICAM1 ADIPOQ
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 SELP MIR21 HGF
4 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.71 MIR21 MIR133A1 ADIPOQ
5 negative regulation of cell migration GO:0030336 9.67 TPM1 MIR21 MIR133A1 ADIPOQ
6 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.63 VCAM1 SELP ICAM1
7 calcium-mediated signaling using intracellular calcium source GO:0035584 9.59 VCAM1 SELP
8 leukocyte tethering or rolling GO:0050901 9.58 VCAM1 SELP
9 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 MIR21 MIR133A1
10 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.58 TPM1 MIR133A1 ADIPOQ
11 positive regulation of smooth muscle cell differentiation GO:0051152 9.52 OLFM2 MIR22
12 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.51 MIR21 IL6
13 leukocyte cell-cell adhesion GO:0007159 9.5 VCAM1 SELP ICAM1
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.49 MIR210 MIR21
15 membrane to membrane docking GO:0022614 9.48 VCAM1 ICAM1
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.46 IL6 ICAM1 HGF ADIPOQ
17 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.43 MIR21 HGF
18 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.43 TPM1 MIR21 ADIPOQ
19 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.13 MIR21 IL6 ICAM1
20 positive regulation of osteoblast differentiation GO:0045669 8.92 MIR210 MIR21 IL6 HGF

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR22 MIR210 MIR21 MIR133A1

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....